OPNT - Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment
- Opiant Pharmaceuticals ( NASDAQ: OPNT ) on Monday said it had been awarded an additional $2.1M of funding by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to support the development of its opioid overdose nasal treatment OPNT003.
- Despite the news, OPNT stock had fallen 16% to $10 in postmarket trading.
- OPNT said the increase in funding from BARDA was primarily for the preparation and filing of a new drug application for OPNT003 with the U.S. FDA.
- Opiant ( OPNT ) had earlier been awarded $8.7M from BARDA, and had also received a $7.4M grant from the National Institute on Drug Abuse.
For further details see:
Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment